Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Achieve Life Sciences Inc. (NASDAQ:ACHV) stock perked up as the company announced received the FDA approval for its IND seeking approval to start U.S. clinical trials assessing smoking cessation drug cytosine. The company has already completed two large-scale Phase 3 studies, TASC and CASCAID, in over 2,000 patients. Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. The company expects to commence a Phase 3 trial of cytisine in the United States in the first-half of 2018.
The company stock perked up over 12 percent in its previous trading session, trimming its Year to Date losses to 39 percent.

Soligenix Inc. ($SNGX) announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has exercised an option to fund GMP (good manufacturing practices) compliant RiVax® bulk drug substance and finished drug product manufacturing. The funding will involve approximately $2.5M in additional non-dilutive funding, bringing the total amount awarded to date under this contract to $21.2M. The company will use the products for future clinical studies.
The funding will help the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax® with the US Food and Drug Administration (FDA).

Anthem ($ANTM) reported that it plans to stop selling Obamacare plans in Virginia. The change will be effective from the next year. The company has already announced its exit from several other states including Indiana, Ohio and Nevada.

Intuitive Surgical ($ISRG) announced that its board has approved a 3:1 split of its common stock. The split is yet to be approved by the shareholders, due by September 22. The post-split trading will commence on October 6.

Shire Plc ($SHPG) announced that its Canadian unit Shire Pharma Canada has the received the Health Canada’s approval for its ONIVYDE (irinotecan liposome injection), in combination with 5-fluorouracil (5-FU) and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine.


Coherus Biosciences ($CHRS) announced that it has terminated its contract with Daiichi Sankyo. The agreement dated back to 2012 and entailed the development of CHS-0214, a biosimilar to Amgen's Enbrel (etanercept), in Japan. Coherus said that there will not be any early termination penalty for it.

NantHealth ($NH) inked a deal with Allscripts for selling its provider/patient engagement assets. The company plans to focus on developing cancer products and trim superfluous assets. The sale assets include the transfer of 15 million common shares already bought by Allscripts.


Alcobra ($ADHD) announced its net loss for the second quarter at $3.7 million. The company did not earn any revenue during the quarter while its R&D expenses stood at $1.4 million. Alcobra reported $2.1 million in SG&A expenses.

Brokerage Action Company Rating Price Target Impact on Share Price
HC Wainwright Initiates Alphatec Holdings (ATEC)
Buy -> Buy $4.00 Low

Cantor Fitzgerald Initiates BioDelivery Sciences International (BDSI)
Overweight $4.50 N/A
HC Wainwright Raises Target Catabasis Pharmaceuticals (CATB)
Buy $9.00 Low

Chardan Capital Reiterates Crispr Theraptc (CRSP)
Buy Low

Chardan Capital Reiterates Dimension Therapeutics (DMTX)
Hold Low

Chardan Capital Reiterates Dicerna Pharmaceuticals (DRNA)
Hold Low

Gainers (% price change) Last Trade Change Mkt Cap
Community Health Systems CYH 7.45 +1.38 (22.73%) 854.95M
STAAR Surgical Company STAA 11.75 +0.90 (8.29%) 483.03M
Sangamo Therapeutics Inc SGMO 10.25 +0.75 (7.89%) 837.96M
Compugen Ltd. (USA) CGEN 3.35 +0.20 (6.35%) 179.69M
Achillion Pharmaceuticals ACHN 4.70 +0.27 (5.98%) 642.10M
Losers (% price change)
Catalyst Pharmaceuticals CPRX 2.72 -0.13 (-4.56%) 229.99M
Utah Medical Products UTMD 69.30 -2.60 (-3.62%) 257.73M
Peregrine Pharmaceuticals PPHM 3.50 -0.13 (-3.58%) 157.74M
Harvard Bioscience, Inc. HBIO 3.05 -0.10 (-3.17%) 106.25M
Synergy Pharmaceuticals SGYP 2.98 -0.09 (-2.93%) 670.35M
Most Actives (dollar volume)
Johnson & Johnson JNJ 133.10 +0.01 (0.01%) 357.24B
Gilead Sciences, Inc. GILD 72.40 -0.30 (-0.41%) 94.55B
Teva Pharmaceutical TEVA 17.30 +0.11 (0.64%) 17.83B
Pfizer Inc. PFE 33.25 -0.17 (-0.51%) 198.01B
UnitedHealth Group Inc UNH 193.02 +0.45 (0.23%) 186.62B